Skip to main content

Michael Evans
Clinical Investigator

AVP, Strategy & Innovation
Co-Director, Center for Pharmacy Innovation and Outcomes


Center for Pharmacy Innovation and Outcomes
100 North Academy Avenue
Danville, PA 17822
Phone: 570-271-6192
Fax: 570-214-2535

Michael A Evans, RPh

Research Interests

Evans is the Associate Vice President of Strategy and Innovation at Geisinger and Co-Director of the Center for Pharmacy Innovation and Outcomes. He is responsible for overall strategy development, administrative oversight and leadership for Ambulatory Clinical Pharmacy Programs which includes all Medication Therapy Disease Management clinics in the Community Practice Service Line primary care clinics and hospital based specialty clinics across the health system, managing disease states such as anticoagulation, diabetes, hypertension, non-malignant chronic pain, hyperlipidemia, congestive heart failure, anemia and oral chemotherapies. He and his 61 ambulatory care team members’ success in pharmacist collaborative practice model of chronic disease management have Geisinger on the forefront of multidisciplinary patient care. His is focused on translational outcomes and healthcare redesign, including: Pharmacy Patient Care Models and System Process Redesign, Pharmacoeconomics and Outcomes research, Medication safety, Pharmacogenomics, Health Information Technology and Adherence.

Recent Publications

  • Jones LK, Greskovic G, Grassi DM, Graham J, Sun H, Gionfriddo MR, Murray MF, Manickam K, Nathanson DC, Wright EA, Evans MA. Medication therapy disease management: Geisinger’s approach to population health management. AJHP. 2017;74(18):1422-1435. Full Text
  • Farah WH, Alsawas M, Mainou M, Alahdab F, Farah MH, Ahmed AT, Mohamed EA, Almasri J, Gionfriddo MR, Castaneda-Guarderas A, Mohammed K, Wang Z, Asi N, Sawchuk CN, Williams MD, Prokop LJ, Murad MH, LeBlanc A. (2016, Dec). Non-pharmacological treatment of depression: a systematic review and evidence map. Evid Based rel="noopener noreferrer" Med, 21(6):214-221. Full Text 
  • Huang RC, Song XT, Wu J, Huang W, Leppin AL, Gionfriddo MR, Liu YX, Boehmer KR, Ting HH, Montori VM. (2016, Nov). Assessing the feasibility and quality of shared decision making in China: evaluating a clinical encounter intervention for Chinese rel="noopener noreferrer" patients. Patient Prefer Adherence, 10:2341-2350. Full Text 
  • Graham J, Sanchez RJ, Saseen J, Mallya UG, Panaccio MP, Evans MA. (2016). Clinical and economic consequences of statin intolerance in the United States: results from an integrated rel="noopener noreferrer" health system. Journal of Clinical Lipidology. [ePub ahead of print] Full Text
  • Chang AR, Evans M, Yule C, Bohn L, Young A, Lewis M, Graboski E, Gerdy B, Ehmann W, Brady J, Lawrence L, Antunes N, Green J, Snyder S, Kirchner HL, Grams M, Perkins R. (2016, Nov). Using pharmacists to improve risk stratification rel="noopener noreferrer" and management of stage 3A chronic kidney disease: a feasibility study. BMC Nephrology, 17(168). Full Text
  • Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Singh P, Lin J . (2016, Jan). Warfarin time in therapeutic range and its impact on rel="noopener noreferrer" healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Curr Med Res Opin , 32(1), 87-94. Full Text
  • Nordstrom BL, Evans MA, Murphy BR, Nutescu EA, Schein JR, Bookhart BK. (2015, March). Risk of rel="noopener noreferrer" recurrent venous thromboembolisum among deep vein thrombosis and pulmonary embolism patients treated with warfarin . Curr Med Res Opin , 31(3), 439-447. Full Text


Registered Pharmacist, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 1996

Additional Links